Kar P K, Dhaka R S
Classified Specialist (Dermatology & Ven), 151 Base Hospital C/O 99 APO, Pune.
Classified Specialist (Pathology), Military Hospital Jalandhar Cantt 144004.
Med J Armed Forces India. 1997 Apr;53(2):91-94. doi: 10.1016/S0377-1237(17)30673-1. Epub 2017 Jun 26.
Efficacy of multi-drug therapy as per WHO recommendation in 125 fresh cases of borderline tuberculoid (BT) leprosy was evaluated. There were 116 (92.8%) male and 9 (7.2%) female patients. Age of the patients ranged from 18-50 years but the majority (80.8%) were young adults in the age group 21-35 years. The commonest site of lesion was the upper extremity in 65 (52%) cases. Skin smear for acid fast was positive in 11 (8.8%) patients. All patients were given multidrug therapy consisting of rifampicin 600 mg once a month and dapsone 100 mg daily for 6 months. At the end of 6 months, 42 (33.6%) patients had shown marked improvement, 14 (11.2%) had increase in activity, 51 (45.6%) had shown regression and 12 (9.6%) cases became clinically inactive. Histologically complete clearance of the infiltration was not observed in any patient. Compact granulomas persisted in 30 (24%) cases. In 1 (0.8%) patient were found in the skin smear at the end of 6 months. This study indicates that treatment with MDT for 6 months is inadequate to treat all types of BT leprosy cases.
对按照世界卫生组织建议采用多药疗法治疗的125例新诊断的界线类偏结核样型（BT）麻风病例的疗效进行了评估。其中男性患者116例（92.8%），女性患者9例（7.2%）。患者年龄在18至50岁之间，但大多数（80.8%）为21至35岁的年轻人。最常见的皮损部位是上肢，共65例（52%）。11例（8.8%）患者的抗酸皮肤涂片呈阳性。所有患者均接受了多药疗法，即每月服用一次600毫克利福平，每日服用100毫克氨苯砜，疗程为6个月。6个月末，42例（33.6%）患者有明显改善，14例（11.2%）病情活动度增加，51例（45.6%）病情出现好转，12例（9.6%）临床症状消失。组织学上，未观察到任何患者的浸润完全清除。30例（24%）患者仍有致密肉芽肿。6个月末，1例（0.8%）患者的皮肤涂片仍呈阳性。本研究表明，采用多药疗法治疗6个月不足以治愈所有类型的BT麻风病例。
